MGC Pharmaceuticals Ltd.

Lapse of Performance Rights, Directors' 3Ys and new London based

Chief Financial Officer

12 April 2022

LSE, ASX: MXC

MGC Pharmaceuticals Ltd ('MGC Pharma' or 'the Company') advises that following on from the Market Release made on 6 April 2022 advising of the lapse of Performance Rights previously granted to directors and employees of the Company, MGC has today released an ASX Appendix 3Y "Change of Director's Interest Notice" for each MGC director detailing the number of Performance Rights that have lapsed for each director.

In addition to the above information the ASX Market Release also contains details of the cessation of the Company's CFO Mr Daniel Kendall, and advises that MGC's Managing Director and CEO, Mr Roby Zomer has assumed the CFO responsibilities while the Company engages a new London based Chief Financial Officer.

A copy of the above ASX Announcement can be found at the following URL:

https://www.asx.com.au/asxpdf/20220412/pdf/457ys9ln4btszj.pdf 

--Ends--

Authorised for release by the Managing Director, for further information please contact:

About MGC Pharma

MGC Pharmaceuticals Ltd (LSE/ASX: MXC) is a European based bio-pharma company developing and supplying affordable standardised phytomedicines to patients globally. The Company's founders were key figures in the global medical cannabis industry and the core business strategy is to develop and supply high quality phytocannabinoid derived medicines for the growing demand in the medical markets in Europe, North America and Australasia. MGC Pharma has a robust product offering targeting two widespread medical conditions - epilepsy and dementia - and has further products in the development pipeline. 

Employing its 'Nature to Medicine' strategy, MGC Pharma has partnered with renowned institutions and academia to optimise cultivation and the development of targeted phytocannabinoid derived medicines products prior to production in the Company's EU-GMP Certified manufacturing facility.  

MGC Pharma has a number of research collaborations with world renowned academic institutions, and including recent research highlighting the positive impact of using specific phytocannabinoid formulations developed by MGC Pharma in the treatment of glioblastoma, the most aggressive and so far therapeutically resistant primary brain tumour.

MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market. 

Follow us through our social media channels:

Twitter: @MGC_Pharma

Facebook: @mgcpharmaceuticals

LinkedIn: MGC Pharmaceuticals Ltd.

Instagram: @mgc_pharma